At a glance
- Originator GlaxoSmithKline
- Class Heart failure therapies
- Mechanism of Action Beta adrenergic receptor antagonists; Phosphoric diester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 21 Jan 2006 Discontinued - Preclinical for Heart failure in USA (unspecified route)
- 04 Dec 2003 No development reported - Preclinical for Heart failure in USA (unspecified route)
- 22 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline